SecBot SecBot
DEFA14A ·Filed Jun 26, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001213900-26-072735
Proxy solicitation materials
Actionable Insight • Neutral

The proxy contest outcome likely favors management given the dissidents' minimal stake and lack of relevant experience. The near-term catalyst is the upcoming 12-month data readout from the COVID-19 Sentinel Cohort, which could significantly impact the stock. Monitor for that data release and any further settlement developments.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5700
T+0 close · Jun 26, 2026 · via day close
Latest settled
−14.04%
T+60 · $0.4900
Vs SPY
−17.08%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $0.5700entry
  2. T+1 · 5mo ago +5.26%α +4.48% · $0.6000
  3. T+5 · 4mo ago +10.44%α +9.05% · $0.6295
  4. T+20 · 4mo ago −21.04%α −20.78% · $0.4501
  5. T+60 · 8w ago −14.04%α −17.08% · $0.4900

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxart filed an updated investor presentation as definitive additional proxy soliciting material, revising details on its $40M financing date, 2025 say-on-pay vote outcome (32.5% support), and rebutting dissident nominee qualifications. The filing is part of an ongoing proxy contest where management urges shareholders to vote FOR all six incumbent directors against a dissident slate holding 0.5% of shares. The company also highlights imminent 12-month safety/immunogenicity data from its BARDA-funded Phase 2b COVID-19 trial (400-subject Sentinel Cohort) and a $29M BARDA funding release, with cash runway into Q2 2027.

Key Financial Metrics

Vote
director election
Seats Contested
3

Key Facts

  • Vaxart updated its investor presentation with revised information on the $40M financing date, 2025 say-on-pay vote outcome (32.5% support), and qualifications of dissident nominees Daniel Houle and Mark Silverberg.
  • Company expects 12-month safety/immunogenicity data from the 400-participant Sentinel Cohort imminently and efficacy data from the ~5,100-participant Main Cohort in H1 2027.
  • BARDA released an additional $29M for trial completion, bringing total available funding to approximately $345M.
  • Cash and cash equivalents were $61M as of March 31, 2026, providing runway into Q2 2027.
  • Board unanimously recommends voting FOR all six director nominees; dissident group holds approximately 0.5% of outstanding shares.
  • Dissident nominees lack public company board experience, clinical-stage biotech expertise, and have not presented credible value-creation ideas.

Financial Impact

No new financial data in this filing; previously disclosed $29M additional BARDA funding and $345M total trial funding reiterated.

cash runwayclinical trial funding

Risk Factors

  • Dissident slate could win if retail shareholders vote for them, though unlikely given their small ownership and lack of qualifications.
  • Clinical trial data may be negative or delayed, impacting the stock.
  • Cash runway only into Q2 2027; additional financing may be needed if milestones are not met.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001213900-26-072735
Document: 0001213900-26-072735-index-headers.html0001213900-26-072735
Document: 0001213900-26-072735-index.html0001213900-26-072735
Document: 0001213900-26-072735.txt0001213900-26-072735

Track record

23 reports on VXRT

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
  2. Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
  3. Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
  4. Jul 7, 202618w ago 8-K Neutral 4/10 Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
  5. Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
  6. Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
  7. Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
  8. Jun 26, 202620w ago DEFA14A Neutral 4/10 Viewing Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  9. Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
  10. Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 26, 2026